THE WOODLANDS,
Texas, March 9, 2017
/PRNewswire/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
announced today that Lexicon management will present at the
Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 3:50 p.m. Eastern Time in Miami. Lexicon management will provide
an overview of Lexicon's clinical development programs and
milestones.
A webcast of the presentation will be available through
Lexicon's website at www.lexpharma.com.
An archived version of the presentation will be available at
www.lexpharma.com until April 14, 2017.
About Lexicon
Lexicon is a fully integrated biopharmaceutical company
that is applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. Lexicon is commercializing XERMELO™
(telotristat ethyl), the first drug from its discovery platform to
receive FDA approval, for carcinoid syndrome diarrhea in
combination with somatostatin analog (SSA) therapy in adults
inadequately controlled by SSA therapy. In addition to
XERMELO, Lexicon has a pipeline of promising drug candidates in
clinical and preclinical development in neuropathic pain, diabetes
and metabolism. For additional information please visit
www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking
statements," including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to meet its capital requirements, successfully
conduct preclinical and clinical development of its drug
candidates, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2016, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-to-present-at-the-barclays-global-healthcare-conference-300420755.html
SOURCE Lexicon Pharmaceuticals, Inc.